Menu
Search
|

Menu

Close
X

Oxford Immunotec Global PLC OXFD.OQ (NASDAQ Stock Exchange Global Market)

18.01 USD
+0.00 (+0.00%)
As of 4:00 PM EDT
chart
Previous Close 18.01
Open 18.01
Volume 35,764
3m Avg Volume 37,438
Today’s High 18.08
Today’s Low 17.88
52 Week High 19.10
52 Week Low 11.80
Shares Outstanding (mil) 26.44
Market Capitalization (mil) 476.17
Forward P/E 44.45
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
67
FY17
88
FY16
86
EPS (USD)
FY18
-0.892
FY17
-0.720
FY16
-1.000
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
44.45
41.05
Price to Sales (TTM)
vs sector
6.86
8.91
Price to Book (MRQ)
vs sector
6.59
4.65
Price to Cash Flow (TTM)
vs sector
39.35
28.95
Total Debt to Equity (MRQ)
vs sector
42.10
17.48
LT Debt to Equity (MRQ)
vs sector
0.13
13.83
Return on Investment (TTM)
vs sector
10.46
12.19
Return on Equity (TTM)
vs sector
13.42
13.29

EXECUTIVE LEADERSHIP

Richard Sandberg
Independent Chairman of the Board, Since 2008
Salary: --
Bonus: --
Peter Wrighton-Smith
Chief Executive Officer, Director, Since 2002
Salary: $404,817.00
Bonus: --
Richard Altieri
Chief Financial Officer, Since 2012
Salary: $315,000.00
Bonus: --
Stefan Linn
Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Elizabeth Keiley
Senior Vice President, General Counsel, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

94C Innovation Drive
ABINGDON     OX14 4RZ

Phone: +441235.442780

Oxford Immunotec Global PLC,is a diagnostics company. It is focused on developing and commercializing tests for under-served immune-regulated conditions. Its product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Tick-borne disease is the collective name for diseases passed to humans through the bite of an infected tick. Its diagnostic tests for tick-borne infections include multiple laboratory developed tests (LDTs). Its tick-borne disease tests utilize molecular methods (such as polymerase chain reaction) and techniques to prosecute the immune system. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease.

SPONSORED STORIES